These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

894 related articles for article (PubMed ID: 19419923)

  • 1. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab for the treatment of advanced non-small-cell lung cancer.
    Manegold C
    Expert Rev Anticancer Ther; 2008 May; 8(5):689-99. PubMed ID: 18471042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Ramalingam S; Belani CP
    Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
    Gridelli C; Maione P; Rossi A; De Marinis F
    Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of antiangiogenic therapy in non-small cell lung cancer.
    Giaccone G
    Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
    Wagstaff AJ; Keam SJ; McCormack PL
    BioDrugs; 2009; 23(3):187-96. PubMed ID: 19627170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
    Hirsh V
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
    Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
    Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB; Johnson DH; Herbst RS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in non-small-cell lung cancer: a review.
    Planchard D
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment for advanced non-small-cell lung cancer.
    Laskin JJ; Sandler AB
    Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in non-small cell lung cancer.
    Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
    Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.